Sensors glean information from radiofrequency ID chips embedded in labels of contrast bottles
VistaTrak looks like a basic cabinet designed to hold bottles of contrast media. Wall-hung and compact, it seems a practical way to keep these bottles handy for use. But mounted to the side of this cabinet is a touchscreen that hints that VistaTrak may be more than it appears.
Lying in wait beneath its simple exterior are sensors that pick up signals from radiofrequency identification (RFID) chips attached to bottles of contrast. These signals indicate the lot number, expiration date, and other information when each bottle is removed from the cabinet. VistaTrak transmits these data to an inventory management system so managers can track the use of contrast and determine when stocks need to be replenished. It even checks automatically for compliance with dosing protocols.
“VistaTrak allows hospitals to not only track their inventory of contrast agents but to watch for patient safety issues, which are becoming critically important when contrast agents are used in an MR or CT suite,” said Douglas Stefanelli, vice president and general manager of diagnostic imaging for Bayer HealthCare Pharmaceuticals. “It also helps compliance with Joint Commission on Accreditation of Healthcare Organizations standards.”
When linked to an electronic medical record or radiology information system, the high-tech cabinet can flag information that may affect the use of contrast material, such as a patient’s glomerular filtration rate (an indicator of kidney disease) or potential allergic reactions, a cochlear implant, or a pacemaker. The password-protected cabinet further safeguards patients by restricting access to staff who are provided specially designed badges or PIN codes.
Previewed by Bayer at RSNA 2007, VistaTrak is scheduled to begin shipping in mid-2008. Bayer’s MR contrast agent Magnevist will be the first to carry a VistaTrak RFID tag.
The cabinet answers some of the challenges facing providers who are being tasked by federal and state regulators, as well as JCAHO, to reduce medication errors. It addresses them in an automated and cost-effective way, according to Scott Bertetti, Bayer’s associate director of business development for diagnostic imaging, using technnology developed by Mobile Aspects and customized by Bayer and Mobile Aspects specifically for the radiology department.
“We created a small cabinet, because real estate is at a premium in the radiology area,” Bertetti said. “We also changed the interface to fit workflow in the radiology department and to address Joint Commission concerns about the use of contrast.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 3rd 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 3rd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 3rd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 3rd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.